Disease landscape

Myelofibrosis clinical trials

Get alerts when Myelofibrosis trials change

258 active trials 155 recruiting 16 Phase 3 137 sponsors 39 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 35 of 39 changes on 19 trials

2026-08-01
Withdrawn before enrolling
Trial withdrawn: In alignment with company strategic direction.
Enrollment reduced: 70 → 0 participants
NCT06290765 Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera · PharmaEssentia · Phase 4
2026-08-18
Withdrawn before enrolling
Trial withdrawn: FDA requested significant changes to the study protocol
Enrollment reduced: 25 → 0 participants
NCT07387354 Pacritinib With Aza for Upfront Myelodysplastic Syndrome · Thomas Jefferson University · Phase 1/2
2026-08-21
Primary completion pushed: 2027-09-16 → 2032-04-05
NCT02386800 CINC424A2X01B Rollover Protocol · Novartis Pharmaceuticals · Phase 4
2026-08-20
Primary completion pushed: 2026-08-31 → 2027-08-31
Completion pushed: 2026-08-31 → 2027-08-31
NCT05600894 Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic… · National Cancer Institute (NCI) · Phase 2
2026-08-18
Primary completion pushed: 2026-02-01 → 2026-12-24
Completion pushed: 2026-06-30 → 2026-12-30
NCT06001385 HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced… · Center for International Blood and Marrow Transplant Research · Phase 2
2026-08-07
Primary completion pushed: 2026-08-31 → 2028-08-31
Completion pushed: 2026-08-31 → 2028-08-31
NCT02861417 Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating… · M.D. Anderson Cancer Center · Phase 2
2026-08-27
Enrollment reduced: 36 → 30 participants
Enrollment closed, study ongoing
NCT05371964 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity… · Geron Corporation · Phase 1
2026-08-13
Enrollment reduced: 186 → 37 participants
Enrollment closed, study ongoing
NCT06313593 A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With… · Incyte Corporation · Phase 1
2026-08-11
Enrollment reduced: 225 → 160 participants
Enrollment closed, study ongoing
NCT05936359 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With… · Incyte Corporation · Phase 1
2026-08-08
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
NCT07708272 QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety… · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 1
2026-08-12
Recruitment resumed after suspension
Enrollment increased: 62 → 78 participants
NCT06661915 A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative… · National Cancer Institute (NCI) · Phase 2
2026-08-18
Recruitment opened
NCT07302776 TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT · Stanford University · Phase 1
2026-08-28
Trial sites expanded: 49 → 53 locations
NCT07357727 A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) · Novartis Pharmaceuticals · Phase 3
2026-08-15
Recruitment opened
NCT07384039 Exercise Training in Patients With Myeloproliferative Neoplasms · Hannover Medical School
2026-08-11
Enrollment closed, study ongoing
Primary completion moved earlier: 2027-05 → 2024-04-04
Completion moved earlier: 2028-05 → 2027-04-04
NCT00935090 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer · Barbara Ann Karmanos Cancer Institute
2026-08-11
Primary completion pushed: 2026-10-19 → 2026-11-19
Completion pushed: 2028-10-19 → 2028-11-19
NCT06361641 Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes · University Hospital, Angers
2026-08-19
Trial sites expanded: 30 → 47 locations
NCT07357727 A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) · Novartis Pharmaceuticals · Phase 3
2026-08-01
Primary completion pushed: 2028-08-01 → 2028-09-01
Completion pushed: 2029-08-01 → 2029-09-01
NCT07679334 Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the… · Roswell Park Cancer Institute · Phase 1
2026-08-14
Trial sites expanded: 2 → 73 locations
NCT06468033 P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk · PharmaEssentia · Phase 3
2026-08-06
Trial sites reduced: 207 → 194 locations
NCT07623161 A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are… · Takeda · Phase 3

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-06 NCT07750574 Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Chengdu Zenitar Biomedical Technology Co., Ltd new Phase 2
2026-07-17 NCT07710534 Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN Virginia Commonwealth University new Phase 2
2026-07-02 NCT07680868 Caris Chromoseq Data Collection Caris Science, Inc. new
2026-06-15 NCT07648433 Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients Weizmann Institute of Science new
2026-06-04 NCT07626021 Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms Zhongshan Hospital (Xiamen), Fudan University new Phase 2

Active trials by phase

Early Phase 1
4
Phase 1
53
Phase 1/2
27
Phase 2
80
Phase 2/3
1
Phase 3
15
Phase 4
2
Not charted: 76 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 258

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT02386800 CINC424A2X01B Rollover Protocol Novartis Pharmaceuticals Active, Not Recruiting 2026-08-20
NCT07498205 Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low… SWOG Cancer Research Network Not Yet Recruiting 2026-08-05
Phase 3
NCT07357727 A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Novartis Pharmaceuticals Recruiting 2026-08-27
NCT07623161 A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are… Takeda Recruiting 2026-08-24
NCT04064060 A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other… Celgene Recruiting 2026-07-01
NCT06351631 A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Merck Sharp & Dohme LLC Recruiting 2026-04-02
NCT05198960 AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic… University Hospital, Brest Recruiting 2026-03-20
NCT06479135 Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With… Kartos Therapeutics, Inc. Recruiting 2025-09-25
NCT06740916 Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients… Siriraj Hospital Recruiting 2024-12-27
NCT02521493 Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or… Children's Oncology Group Active, Not Recruiting 2026-08-19
NCT06468033 P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk PharmaEssentia Active, Not Recruiting 2026-08-13
NCT04603495 Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Novartis Pharmaceuticals Active, Not Recruiting 2026-07-17
NCT04717414 An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With… Celgene Active, Not Recruiting 2026-07-16
NCT04576156 A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of… Geron Corporation Active, Not Recruiting 2026-07-08
NCT03165734 A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia… Swedish Orphan Biovitrum Active, Not Recruiting 2026-04-30
NCT04562389 Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Karyopharm Therapeutics Inc Active, Not Recruiting 2026-04-09
NCT04468984 Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best… AbbVie Active, Not Recruiting 2026-01-09
Phase 2/3
NCT07539779 Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With… Nanfang Hospital, Southern Medical University Not Yet Recruiting 2026-04-20
Phase 2
NCT05554406 Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed… National Cancer Institute (NCI) Recruiting 2026-08-27
NCT05564390 MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study… National Cancer Institute (NCI) Recruiting 2026-08-27
NCT04493164 CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or… M.D. Anderson Cancer Center Recruiting 2026-08-25
NCT06345495 High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients… M.D. Anderson Cancer Center Recruiting 2026-08-20
NCT06661915 A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative… National Cancer Institute (NCI) Recruiting 2026-08-19
NCT07148947 Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic… University of Washington Recruiting 2026-08-19
NCT07228624 Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With… Fred Hutchinson Cancer Center Recruiting 2026-08-19
See all 258 active Myelofibrosis trials with filters →

Top sponsors by active trials in this area

M.D. Anderson Cancer Center (18) · City of Hope Medical Center (10) · National Cancer Institute (NCI) (8) · Fred Hutchinson Cancer Center (7) · Incyte Corporation (7) · Memorial Sloan Kettering Cancer Center (6) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (5) · University Hospital, Angers (5) · AbbVie (4) · Azienda Ospedaliero-Universitaria di Parma (4)

Get alerts when Myelofibrosis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free